Hutchmed

News

Hutchmed rises on $1.3bn KRAS licensing deal with GSK

GSK has paid Hutchmed $110m upfront for rights to a preclinical KRAS and EGFR-directed drug with potential in colorectal, pancreatic, and lung cancer.

News

Hutchmed scores with drug for rare autoimmune disease

Hutchmed is preparing to file for approval of its drug for the rare disorder wAIHA in China, after chalking up a win in a pivotal phase 2/3 trial.

News

Hutchmed cashes in a Chinese JV to help fund its pipeline

Hutchmed has agreed to divest its share of a non-core Chinese JV through a pair of deals that will give it a cash injection to plough into R&D.

News

Hutchmed files Takeda-partnered colorectal cancer drug in US

Chinese biotech Hutchmed has completed its rolling marketing application in the US for oral VEGF receptor inhibitor fruquintinib, which was licensed by Takeda for a hefty

News

Takeda grabs ex-China fruquintinib rights from Hutchmed

Chinese biotech Hutchmed's push to sign partnerships for its drug products outside its home market has resulted in a $1.13 billion deal with Japan's Takeda, including a hefty upfront fee of

News

Tagrisso paired with Hutchmed drug clears lung cancer test

EGFR inhibitors like AstraZeneca's Tagrisso have been hugely successful in treating EGFR-positive lung cancer, but the durability of treatment is often reduced by resistance mutations.

Hutchmed rises on $1.3bn KRAS licensing deal with GSK

Hutchmed scores with drug for rare autoimmune disease

Hutchmed cashes in a Chinese JV to help fund its pipeline

Hutchmed files Takeda-partnered colorectal cancer drug in US

Takeda grabs ex-China fruquintinib rights from Hutchmed

Tagrisso paired with Hutchmed drug clears lung cancer test

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Hutchmed

Editor's Picks